Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

59.37 +1.98 (+3.45%)

Streaming Delayed Price Updated: 1:33 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

88 89 Next >

3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade ↗

August 20, 2024

With yields above 4%, these stocks could do a lot to boost your passive income stream

Via The Motley Fool

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

August 19, 2024

From Bristol Myers Squibb

Via Business Wire

Where Will Bristol Myers Squibb Be in 5 Years? ↗

August 18, 2024

The drugmaker will go through key changes by the end of the decade.

Via The Motley Fool

3 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗

August 18, 2024

ETFs offer a good way to own a diversified portfolio of income-producing equities.

Via The Motley Fool

Topics ETFs

Check Out What Whales Are Doing With BMY ↗

August 16, 2024

Via Benzinga

Smart Money Is Betting Big In BMY Options ↗

August 09, 2024

Via Benzinga

Smart Money Is Betting Big In BMY Options ↗

August 06, 2024

Via Benzinga

Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations ↗

August 15, 2024

Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.

Via Benzinga

Topics Economy

Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' ↗

August 14, 2024

Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction.

Via Benzinga

Topics Workforce

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗

August 13, 2024

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...

Via Benzinga

The 3 Best Healthcare Stocks to Buy in August 2024 ↗

August 12, 2024

These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.

Via InvestorPlace

Bristol-Myers Squibb Co: Is It A Buy? ↗

August 11, 2024

As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:...

Via Talk Markets

3 Stocks Retirees Should Absolutely Love ↗

August 10, 2024

All of these stocks can provide steady income to retired investors.

Via The Motley Fool

3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗

August 08, 2024

The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.

Via InvestorPlace

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗

August 05, 2024

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...

Via Benzinga

Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever. ↗

August 05, 2024

Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.

Via The Motley Fool

MarketBeat Week in Review – 7/29 - 8/2

August 03, 2024

The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move

Via MarketBeat

Topics Economy Stocks

The 3 Biggest Earnings Beats for Q2 as of August 1, 2024 ↗

August 01, 2024

The stocks serving up the biggest earnings beats may just go on to offer investors fabulous returns going forward.

Via InvestorPlace

Topics Earnings

8 Health Care Stocks With Whale Alerts In Today's Session ↗

August 01, 2024

Via Benzinga

Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore ↗

August 01, 2024

These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment.

Via InvestorPlace

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗

July 31, 2024

Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.

Via InvestorPlace

The Top 3 Healthcare Stocks to Buy Now: Summer 2024 ↗

July 31, 2024

Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages.

Via InvestorPlace

Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far ↗

July 30, 2024

3M soared over 20% since it reported strong earnings on July 26, while Ford is down over 20% since its report on July 24.

Via Benzinga

Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗

July 30, 2024

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2024

Via Benzinga

Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer ↗

July 30, 2024

The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...

Via Benzinga

Market Momentum: Your Weekly Financial Forecast ↗

July 30, 2024

Originally published at VolumeLeaders What to expect for July 29- August 02, 2024

Via Benzinga

Is Bristol Myers Squibb a Good Dividend Stock to Buy Now? ↗

July 30, 2024

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.

Via The Motley Fool

Topics Intellectual Property

Healthcare Stocks Are Coming On Strong In July Led By Biotech ↗

July 29, 2024

The biotech rally gained momentum in July with rotation out of technology stocks.

Via Talk Markets

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings ↗

July 29, 2024

Bristol-Myers Squibb's stock rallies after Q2 results. Analysts have mixed views on the performance and management commentary.

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

88 89 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.